RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. EBITDA margin (%)

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 202431.5-7.52%
Dec 31, 202334.1-18.38%
Dec 31, 202241.7-27.35%
Dec 31, 202157.4+28.04%
Dec 31, 202044.9+45.79%
Dec 31, 201930.8-23.01%
Dec 31, 201840+5.50%
Dec 31, 201737.9+28.30%
Dec 31, 201629.5-8.65%
Dec 31, 201532.3+2.30%
Dec 31, 201431.6-16.98%
Dec 31, 201338.1+6.09%
Dec 31, 201235.9-311.78%
Dec 31, 2010-16.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)